Lupus nephritis | Without Lupus nephritis | P value | |
---|---|---|---|
Number of patients, n (%) | 45 (36%) | 89 (66.4%) | |
SLICC at last clinical assessment | 0 | 0 (0- 0.5) | 0.872 |
SLEDAI at last clinical assessment | 2 (0- 4) | 0 (0- 2) | 0.123 |
BILAG at last clinical assessment | 1 (0- 1.75) | 1 (0- 1) | 0.822 |
Constitutional symptoms | 26 (80%) | 67 (75.3%) | 0.666 |
Mouth ulcers | 31 (68.8%) | 61 (68.5%) | 0.258 |
Skin involvement | 40 (88.9%) | 73 (82%) | 0.150 |
Arthritis | 37 (82.2%) | 71 (79.8%) | 0.309 |
Myositis | 5 (11.1%) | 16 (18%) | 0.451 |
Neuropsychiatric involvement | 15 (33.3%) | 19 (21.3%) | 0.146 |
Cardiorespiratory involvement | 12 (26.7%) | 20 (22.5%) | 0.669 |
Gastrointestinal involvement | 8 (17.8%) | 18 (20.2%) | 0.724 |
Ophthalmic involvement | 4 (8.9%) | 9 (10.1%) | 0.108 |
Haematological involvement | 26 (57.8%) | 44 (49.4%) | 0.464 |
Hypertension | 8 (17.8%) | 6 (6.7%) | 0.071 |
Stroke | 1 (2.2%) | 2 (2.2%) | 1.000 |
Low bone mineral density | 16 (35.5%) | 11 (12.4%) | 0.008* |
Malignancy | 1 (2.2%) | 1 (1.1%) | 1.000 |
Numbers are medians (interquartile ranges) unless otherwise stated. *p<0.05 is significant